p.92 抽出テキスト

589. Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 2010;25:853–858. https://doi.org/10.1007/s11606-010-1340-y 590. Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case–control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 2011; 108:56–62. https://doi.org/10.1016/j.amjcard.2011.03.004 591. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–988. https://doi.org/10.1161/01. str.22.8.983 592. Mahmoodi BK, Yatsuya H, Matsushita K, Sang Y, Gottesman RF, Astor BC, et al. Association of kidney disease measures with ischemic versus hemorrhagic strokes: pooled analyses of 4 prospective community-based cohorts. Stroke 2014;45: 1925–1931. https://doi.org/10.1161/STROKEAHA.114.004900 593. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ Res 2017;120:472–495. https://doi.org/10.1161/CIRCRESAHA.116.308398 594. Patlolla SH, Lee H-C, Noseworthy PA, Wysokinski WE, Hodge DO, Greene EL, et al. Impact of diabetes mellitus on stroke and survival in patients with atrial fibrillation. Am J Cardiol 2020;131:33–39. https://doi.org/10.1016/j.amjcard.2020.06.049 595. Melduni RM, Lee H-C, Bailey KR, Miller FA Jr, Hodge DO, Seward JB, et al. Real-time physiologic biomarker for prediction of atrial fibrillation recurrence, stroke, and mortality after electrical cardioversion: a prospective observational study. Am Heart J 2015; 170:914–922. https://doi.org/10.1016/j.ahj.2015.07.027 596. Karayiannides S, Norhammar A, Landstedt-Hallin L, Friberg L, Lundman P. Prognostic impact of type 1 and type 2 diabetes mellitus in atrial fibrillation and the effect of severe hypoglycaemia: a nationwide cohort study. Eur J Prev Cardiol 2022;29:1759–1769. https://doi.org/10.1093/eurjpc/zwac093 597. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476–484. https://doi.org/10.1016/S0002-9343(99)80348-9 598. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 2008;117:1255–1260. https://doi.org/10.1161/CIRCULATIONAHA. 107.744466 599. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident atrial fibrillation in women. J Am College Cardiol 2012;60:1421–1428. https://doi. org/10.1016/j.jacc.2012.06.030 600. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42: 373–498. https://doi.org/10.1093/eurheartj/ehaa612 601. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol 2014;114:1217–1222. https://doi. org/10.1016/j.amjcard.2014.07.045 602. Liou Y-S, Yang F-Y, Chen H-Y, Jong G-P. Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study. PLoS One 2018;13: e0197245. https://doi.org/10.1371/journal.pone.0197245 603. Zelniker TA, Bonaca MP, Furtado RH, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation 2020;141:1227–1234. https://doi.org/ 10.1161/CIRCULATIONAHA.119.044183 604. Böhm M, Slawik J, Brueckmann M, Mattheus M, George JT, Ofstad AP, et al. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. Eur J Heart Fail 2020;22:126–135. https://doi. org/10.1002/ejhf.1663 605. Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, et al. Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am College Cardiol 2021;78:142–152. https://doi.org/10.1016/j.jacc.2021. 04.079 606. Neefs J, Van den Berg N, Limpens J, Berger W, Boekholdt S, Sanders P, et al. Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 2017;231:155–161. https://doi.org/10.1016/j.ijcard.2016. 12.029 607. Du X, Ninomiya T, De Galan B, Abadir E, Chalmers J, Pillai A, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009;30: 1128–1135. https://doi.org/10.1093/eurheartj/ehp055 608. Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol 2008;101:634–638. https://doi. org/10.1016/j.amjcard.2007.10.025 609. Gallagher C, Hendriks JM, Mahajan R, Middeldorp ME, Elliott AD, Pathak RK, et al. Lifestyle management to prevent and treat atrial fibrillation. Expert Rev Cardiovas Ther 2016;14:799–809. https://doi.org/10.1080/14779072.2016.1179581 610. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124. https://doi.org/10. 1136/bmj.d124 611. Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 2009;32:1851–1856. https://doi.org/10.2337/dc09-0939 612. Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, et al. Screening for atrial fibrillation: a report of the AF-SCREEN International Collaboration. Circulation 2017;135:1851–1867. https://doi.org/10.1161/CIRCULATIONAHA.116.026693 613. Svennberg E, Tjong F, Goette A, Akoum N, Di Biase L, Bordachar P, et al. How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace 2022;24:979–1005. https://doi.org/10.1093/europace/euac038 614. Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace 2017;19:1589–1623. https://doi.org/10.1093/europace/eux177 615. Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 2009;20:22–28. https://doi.org/10.1111/j.1540-8167.2008. 01275.x 616. Anselmino M, Matta M, D’ascenzo F, Pappone C, Santinelli V, Bunch TJ, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and meta-analysis. Europace 2015;17:1518–1525. https://doi.org/10.1093/europace/ euv214 617. Bogossian H, Frommeyer G, Brachmann J, Lewalter T, Hoffmann E, Kuck KH, et al. Catheter ablation of atrial fibrillation and atrial flutter in patients with diabetes mellitus: who benefits and who does not? Data from the German ablation registry. Int J Cardiol 2016;214:25–30. https://doi.org/10.1016/j.ijcard.2016.03.069 618. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest 2010;137: 263–272. https://doi.org/10.1378/chest.09-1584 619. Hughes M, Lip GY. Guideline Development Group for the NICE National Clinical Guideline for Management of Atrial Fibrillation in Primary Secondary Care. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008;99: 295–304. https://doi.org/10.1160/TH07-08-0508 620. Aronow WS, Ahn C, Kronzon I, Gutstein H. Risk factors for new thromboembolic stroke in patients ≥62 years of age with chronic atrial fibrillation. Am J Cardiol 1998; 82:A9. https://doi.org/10.1016/S0002-9149(98)00247-1 621. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69:546–554. https://doi.org/10.1212/01.wnl.0000267275.68538.8d 622. Wang A, Green JB, Halperin JL, Piccini JP. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am College Cardiol 2019;74:1107–1115. https://doi.org/10. 1016/j.jacc.2019.07.020 623. Proietti M, Lane DA, Boriani G, Lip GY. Stroke prevention, evaluation of bleeding risk, and anticoagulant treatment management in atrial fibrillation contemporary international guidelines. Can J Cardiol 2019;35:619–633. https://doi.org/10.1016/j.cjca. 2019.02.009 624. Fauchier L, Bodin A, Bisson A. Editorial commentary: the CHA2DS2VASc score and its black and white items. Trends Cardiovasc Med 2019;29:392–393. https://doi.org/10. 1016/j.tcm.2018.11.012 625. Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GY, et al. Glycemic status and thromboembolic risk in patients with atrial fibrillation and type 2 diabetes mellitus: a Danish cohort study. Circ Arrhythm Electrophysiol 2019;12:e007030. https:// doi.org/10.1161/CIRCEP.118.007030 626. Lip GY, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2015;147:1103–1110. https:// doi.org/10.1378/chest.14-2096 627. Itzhaki Ben Zadok O, Eisen A. Use of non-vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus. Diabet Med 2018;35:548–556. https://doi.org/ 10.1111/dme.13600 628. Plitt A, McGuire DK, Giugliano RP. Atrial fibrillation, type 2 diabetes, and non–vitamin K antagonist oral anticoagulants: a review. JAMA Cardiol 2017;2:442–448. https://doi. org/10.1001/jamacardio.2016.5224 629. Plitt A, Zelniker TA, Park J-G, McGuire DK, Ruff CT, Antman EM, et al. Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58634 patients across four randomized Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026